Diversified Trust Co increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 71.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,080 shares of the medical research company’s stock after purchasing an additional 1,696 shares during the quarter. Diversified Trust Co’s holdings in Thermo Fisher Scientific were worth $1,801,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Copper Rock Capital Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $265,775,000. BlackRock Inc. lifted its holdings in shares of Thermo Fisher Scientific by 7.1% during the second quarter. BlackRock Inc. now owns 28,955,941 shares of the medical research company’s stock worth $10,491,896,000 after buying an additional 1,929,802 shares during the last quarter. Viking Global Investors LP acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $628,350,000. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 8.0% during the first quarter. Capital World Investors now owns 16,824,726 shares of the medical research company’s stock worth $4,771,494,000 after buying an additional 1,242,140 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in shares of Thermo Fisher Scientific by 112.6% during the second quarter. Nordea Investment Management AB now owns 1,400,982 shares of the medical research company’s stock worth $494,098,000 after buying an additional 741,998 shares during the last quarter. 88.12% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have recently issued reports on TMO shares. Needham & Company LLC boosted their price objective on Thermo Fisher Scientific from $468.00 to $477.00 and gave the company a “buy” rating in a research report on Thursday, September 17th. Atlantic Securities began coverage on Thermo Fisher Scientific in a research report on Wednesday, September 30th. They issued an “overweight” rating and a $494.00 price target on the stock. SVB Leerink upped their price target on Thermo Fisher Scientific from $455.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday, September 11th. JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $460.00 to $480.00 and gave the company an “overweight” rating in a research report on Monday, October 5th. Finally, Argus upped their price target on Thermo Fisher Scientific from $370.00 to $450.00 in a research report on Monday, July 27th. Two equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $452.27.
NYSE:TMO traded up $4.03 during mid-day trading on Friday, hitting $468.59. The company had a trading volume of 1,070,263 shares, compared to its average volume of 1,656,574. Thermo Fisher Scientific Inc. has a fifty-two week low of $250.21 and a fifty-two week high of $473.84. The business’s fifty day moving average is $433.77 and its two-hundred day moving average is $378.29. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.02 and a current ratio of 2.62. The firm has a market cap of $185.37 billion, a P/E ratio of 50.71, a P/E/G ratio of 1.88 and a beta of 1.01.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 earnings per share for the quarter, beating the consensus estimate of $2.67 by $1.22. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The firm had revenue of $6.92 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the firm posted $3.04 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 15.27 earnings per share for the current year.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction dated Friday, July 24th. The stock was sold at an average price of $403.37, for a total value of $8,067,400.00. Following the sale, the chief executive officer now owns 260,446 shares in the company, valued at approximately $105,056,103.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jim P. Manzi sold 3,218 shares of the company’s stock in a transaction dated Friday, July 24th. The shares were sold at an average price of $402.38, for a total value of $1,294,858.84. Following the completion of the sale, the director now owns 21,803 shares in the company, valued at approximately $8,773,091.14. The disclosure for this sale can be found here. In the last quarter, insiders sold 173,868 shares of company stock worth $71,253,379. Corporate insiders own 0.44% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
Further Reading: Trading Ex-Dividend Strategy
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.